The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CYP1A1*2A polymorphism as a prognostic factor for the advanced lung cancer patients treated with EGFR-TKI and its correlation with EGFR mutation.
Q. Nie
No relevant relationships to disclose
S. An
No relevant relationships to disclose
X. Yang
No relevant relationships to disclose
W. Zhong
No relevant relationships to disclose
R. Liao
No relevant relationships to disclose
J. Yang
No relevant relationships to disclose
X. Zhang
No relevant relationships to disclose
Z. Chen
No relevant relationships to disclose
J. Su
No relevant relationships to disclose
Z. Xie
No relevant relationships to disclose
Y. Huang
No relevant relationships to disclose
Y. L. Wu
No relevant relationships to disclose